Literature DB >> 17482152

Changes in classic and alternative pathways of bile acid synthesis in chronic liver disease.

Andrea Crosignani1, Marina Del Puppo, Matteo Longo, Emma De Fabiani, Donatella Caruso, Massimo Zuin, Mauro Podda, Norman B Javitt, Marzia Galli Kienle.   

Abstract

BACKGROUND: Cholesterol elimination occurs through bile acid synthesis that starts within the liver from 7alpha-hydroxylation or in extrahepatic tissues from 27-hydroxylation. This study was aimed at investigating in vivo these two pathways in patients with chronic liver disease.
METHODS: Serum concentrations of 7alpha- and 27-hydroxycholesterol were measured in 54 patients (29 with primary biliary cirrhosis and 25 with chronic hepatitis C) and 18 controls. The rate of oxysterol plasma appearance was calculated after intravenous infusions of deuterated 7alpha- and 27-hydroxycholesterol in patients (n=8) and control subjects (n=8) who gave consent. The expression of sterol 27-hydroxylase was evaluated in macrophages isolated from 20 subjects.
RESULTS: In patients with liver disease, the rate of plasma appearance of 7alpha-hydroxycholesterol was significantly reduced (1.44+/-0.96 vs. 2.75+/-1.43 mg/hour, p=0.03), the degree of reduction being related with the severity of the disease (p=0.01) whereas that of 27-hydroxycholesterol was unaffected. The rate of plasma appearance of 27-hydroxycholesterol was significantly related to its serum concentrations (r=0.54, p=0.03) and to its release from cultured macrophages ( r=0.85, p=0.03).
CONCLUSIONS: In liver disease 7alpha-hydroxylation of cholesterol seems to be impaired while 27-hydroxylation is unaffected. Serum concentrations of 27-hydroxycholesterol are useful to obtain information on the activity of this alternative pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482152     DOI: 10.1016/j.cca.2007.03.025

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice.

Authors:  Julia Yue Cui; Lauren M Aleksunes; Yuji Tanaka; Zidong Donna Fu; Ying Guo; Grace Liejun Guo; Hong Lu; Xiao-Bo Zhong; Curtis D Klaassen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-01-19       Impact factor: 4.052

2.  Liver metabolomics identifies bile acid profile changes at early stages of alcoholic liver disease in mice.

Authors:  Georgia Charkoftaki; Wan Ying Tan; Pablo Berrios-Carcamo; David J Orlicky; Jaya Prakash Golla; Rolando Garcia-Milian; Reza Aalizadeh; Nikolaos S Thomaidis; David C Thompson; Vasilis Vasiliou
Journal:  Chem Biol Interact       Date:  2022-04-14       Impact factor: 5.168

Review 3.  Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration.

Authors:  Bart Staels; Vivian A Fonseca
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

4.  Chlorpromazine-induced perturbations of bile acids and free fatty acids in cholestatic liver injury prevented by the Chinese herbal compound Yin-Chen-Hao-Tang.

Authors:  Qiaoling Yang; Fan Yang; Xiaowen Tang; Lili Ding; Ying Xu; Yinhua Xiong; Zhengtao Wang; Li Yang
Journal:  BMC Complement Altern Med       Date:  2015-04-16       Impact factor: 3.659

5.  Effects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approach.

Authors:  Gaetano Serviddio; Francesco Bellanti; Rosanna Villani; Rosanna Tamborra; Chiara Zerbinati; Maria Blonda; Marco Ciacciarelli; Giuseppe Poli; Gianluigi Vendemiale; Luigi Iuliano
Journal:  Redox Biol       Date:  2016-09-09       Impact factor: 11.799

Review 6.  The use of stable and radioactive sterol tracers as a tool to investigate cholesterol degradation to bile acids in humans in vivo.

Authors:  Marco Bertolotti; Andrea Crosignani; Marina Del Puppo
Journal:  Molecules       Date:  2012-02-16       Impact factor: 4.411

7.  Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease.

Authors:  April D Lake; Petr Novak; Petia Shipkova; Nelly Aranibar; Donald Robertson; Michael D Reily; Zhenqiang Lu; Lois D Lehman-McKeeman; Nathan J Cherrington
Journal:  Toxicol Appl Pharmacol       Date:  2013-02-04       Impact factor: 4.219

8.  Polysome profiling in liver identifies dynamic regulation of endoplasmic reticulum translatome by obesity and fasting.

Authors:  Suneng Fu; Jason Fan; Joshua Blanco; Alfredo Gimenez-Cassina; Nika N Danial; Steve M Watkins; Gökhan S Hotamisligil
Journal:  PLoS Genet       Date:  2012-08-23       Impact factor: 5.917

Review 9.  Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.

Authors:  Eric Kwong; Yunzhou Li; Phillip B Hylemon; Huiping Zhou
Journal:  Acta Pharm Sin B       Date:  2015-02-09       Impact factor: 11.413

10.  Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-) mouse model.

Authors:  Motoko Kuba; Takashi Matsuzaka; Rie Matsumori; Ryo Saito; Naoko Kaga; Hikari Taka; Kei Ikehata; Naduki Okada; Takuya Kikuchi; Hiroshi Ohno; Song-Iee Han; Yoshinori Takeuchi; Kazuto Kobayashi; Hitoshi Iwasaki; Shigeru Yatoh; Hiroaki Suzuki; Hirohito Sone; Naoya Yahagi; Yoji Arakawa; Tsutomu Fujimura; Yoshimi Nakagawa; Nobuhiro Yamada; Hitoshi Shimano
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.